Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids☆,☆☆,★
Section snippets
Subjects
The subjects were two boys and two girls, aged 3 months to 27 months, treated for KD at the Children's Hospital, Boston, between June 1990 and October 1994. All children met the Centers for Disease Control and Prevention criteria for the diagnosis of KD.4 All patients were treated initially within the first 10 days of onset of fever and were given aspirin, 80 to 100 mg/kg per day, and IVIG (IVEEGAM, Immuno AG, Vienna, Austria), 2 gm/kg in a single infusion during an 8- to 10-hour period.
Corticosteroid therapy
RESULTS
Children who were treated with methylprednisolone had a median age of 10 months (range, 3 months to 27 months); three were less than 1 year of age and two were boys (Table). In each child who was so treated, the fever was attributable to active KD and there were no clinical indications of disease other than KD at the time of treatment (e.g., arthritis, intercurrent infection). All children were receiving high doses of aspirin or ibuprofen at the time of retreatment.
The four patients with
DISCUSSION
A subgroup of patients with KD is resistant to IVIG therapy3; these patients are at greatest risk of development of coronary artery aneurysms and long-term sequelae of the disease. No effective treatment for these patients with refractory disease has been established, but the use of corticosteroids is thought to be contraindicated. Prednisone and related medications are the treatment of choice in other forms of vasculitis, but they are considered to be unsafe in KD.6 This conclusion is based
References (16)
- et al.
Gamma globulin re-treatment in Kawasaki disease
J PEDIATR
(1993) - et al.
Kawasaki disease: clinical perspective
J PEDIATR
(1987) - et al.
The treatment of Kawasaki syndrome with intravenous gamma globulin
N Engl J Med
(1986) - et al.
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome
N Engl J Med
(1991) Kawasaki disease—New York
MMWR Morb Mortal Wkly Rep
(1980)Report of the Subcommittee on Standardization of Diagnostic Criteria and Reporting on Coronary Artery Lesions in Kawasaki Disease
(1984)- et al.
Textbook of pediatric rheumatology
- et al.
Kawasaki disease: effect of treatment on coronary artery involvement
Pediatrics
(1979)
Cited by (229)
Kawasaki Disease
2017, Principles and Practice of Pediatric Infectious DiseasesPreventing coronary artery lesions in Kawasaki disease
2017, Biomedical JournalIntravenous immunoglobulin, pharmacogenomics, and Kawasaki disease
2016, Journal of Microbiology, Immunology and InfectionDiagnosis, Progress, and Treatment Update of Kawasaki Disease
2023, International Journal of Molecular SciencesPediatric expert consensus on the application of glucocorticoids in Kawasaki disease
2022, Chinese Journal of Contemporary Pediatrics
- ☆
From the Department of Medicine, Division of Immunology (Rheumatology), and the Department of Cardiology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
- ☆☆
Reprint requests: Dowain A. Wright, MD, PhD, Division of Immunology, Children's Hospital, 300 Longwood, Ave., Enders 8, Boston, MA 02115.
- ★
0022-3476/96 $5.00 + 0 9/26/68657